Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Shares Outstanding (Weighted Average) (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Shares Outstanding (Weighted Average) data on record, last reported at $7.4 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 1081.39% year-over-year to $7.4 million; the TTM value through Sep 2025 reached $7.4 million, up 1081.39%, while the annual FY2024 figure was $736339.0, 9191.34% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $7.4 million in Q3 2025 per TNXP's latest filing, up from $7.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $10.3 million in Q1 2023 and bottomed at $7925.0 in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $3.1 million, with a median of $724190.0 recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 99.73% in 2024, then skyrocketed 21155.22% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $7925.0 in 2023, then skyrocketed by 9191.34% to $736339.0 in 2024, then soared by 905.43% to $7.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $7.4 million in Q3 2025, $7.3 million in Q2 2025, and $5.9 million in Q1 2025.